
Bicycle Therapeutics is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 119 staff and has a trailing 12-month revenue of around $15 million.
How to buy Bicycle Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – BCYC. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Bicycle Therapeutics stock price (NASDAQ: BCYC)
Use our graph to track the performance of BCYC stocks over time.Bicycle Therapeutics shares at a glance
Latest market close | $27.96 |
---|---|
52-week range | $12.08 - $51.93 |
50-day moving average | $29.08 |
200-day moving average | $24.21 |
Wall St. target price | $53.64 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.91 |
Buy Bicycle Therapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Bicycle Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bicycle Therapeutics price performance over time
Historical closes compared with the close of $27.96 from 2023-01-25
1 week (2023-01-20) | 1.82% |
---|---|
1 month (2022-12-27) | -1.27% |
3 months (2022-10-27) | 16.50% |
6 months (2022-07-27) | 14.83% |
1 year (2022-01-27) | -39.64% |
---|---|
2 years (2021-01-27) | 8.92% |
3 years (2020-01-27) | 151.89% |
5 years (2018-01-23) | N/A |
Bicycle Therapeutics financials
Revenue TTM | $15 million |
---|---|
Gross profit TTM | $-33,183,000 |
Return on assets TTM | -18.34% |
Return on equity TTM | -43.79% |
Profit margin | 0% |
Book value | $9.75 |
Market capitalisation | $816.5 million |
TTM: trailing 12 months
Bicycle Therapeutics share dividends
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Bicycle Therapeutics share price volatility
Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $12.08 up to $51.932. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is 0.7746. This would suggest that Bicycle Therapeutics's shares are less volatile than average (for this exchange).
Bicycle Therapeutics overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics in the news

Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium

Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Frequently asked questions
What percentage of Bicycle Therapeutics is owned by insiders or institutions?Currently 9.978% of Bicycle Therapeutics shares are held by insiders and 91.668% by institutions. How many people work for Bicycle Therapeutics?
Latest data suggests 119 work at Bicycle Therapeutics. When does the fiscal year end for Bicycle Therapeutics?
Bicycle Therapeutics's fiscal year ends in December. Where is Bicycle Therapeutics based?
Bicycle Therapeutics's address is: Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT What is Bicycle Therapeutics's ISIN number?
Bicycle Therapeutics's international securities identification number is: US0887861088 What is Bicycle Therapeutics's CUSIP number?
Bicycle Therapeutics's Committee on Uniform Securities Identification Procedures number is: 088786108
More guides on Finder
-
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert